FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) (“CardioComm Solutions” or the “Company”) today confirmed it has released a new version of its GEMS Home software to support the prescription model of the HeartCheck™ ECG Monitor. GEMS Home 1.2 is now available at no cost to new and current owners of both the consumer and prescription models of the HeartCheck™ ECG devices.
The newest GEMS Home release now enables purchasers of the prescription HeartCheck™ ECG Monitor to benefit from the easy to use GEMS Home ECG management system and to request physician interpretations through the Company’s SMART Monitoring ECG service. GEMS Home will also allow HeartCheck™ customers the option to pre-pay for a set of physician ECG interpretation reports, offering a discounted per electrocardiogram (“ECG”) interpretation rate for the bulk purchase.
Prior to this release, the prescription model of the HeartCheck™ ECG Monitor would only permit ECG uploads directly to a pre-identified physician. While a popular solution for the support of research studies and for use in long-term care facilities, this workflow was problematic for physicians who want their patients to monitor their own cardiac rhythm.
“While prescribing physicians were very interested to see interpretive ECG reports from when their patients felt symptomatic, physicians were less interested to be the first line of support to read the ECGs themselves. With GEMS Home 1.2 patients can manage all ECG recordings themselves and submit them to our SMART Monitoring ECG service at any time. The same per ECG fee of $12.50 for a 30 minute average response time for a physician reading applies as with the consumer HeartCheck™ PEN model. We are examining models for these ECG readings to be covered through health insurance given the HeartCheck™ ECG monitor’s use would be under the prescription of a physician,” said Etienne Grima, Chief Executive Office of CardioComm Solutions.
CardioComm Solutions is committed to enhancing its consumer facing GEMS Home software technologies in response to market feedback for ways to expand use of its HeartCheck™ devices by consumers and patients. “This new software release marks an important first step towards our goal of developing a device agnostic SMART Monitoring ECG service platform of which will support both our own and other ECG monitoring devices. We have attracted a lot of interest from well qualified device manufacturers who see the immediate benefit and fast cycle to marketability from the expansion of our FDA OTC clearances to their products,” stated Simi Grosman, member of the Company’s Board of Directors.
The Company has previously reported that the HeartCheck™ PEN ECG device and GEMS Home software remains the only FDA cleared and Health Canada approved OTC medical monitoring device in North America that is permitted to show a person their own heart ECG without a physician prescription. GEMS Home enables heart rhythm recordings to be moved from the HeartCheck™ devices to a computer for review. GEMS Home is also the gateway to the Company’s patent pending SMART Monitoring ECG service which is central to consumers unlocking the HeartCheck™ PEN and seeing their ECG while recording, in playback or within GEMS Home.
More information regarding the HeartCheck™ products and SMART monitoring solutions is available at the Company’s web site www.theheartcheck.com.
CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Canada, with offices in Victoria, B.C.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.